Anti-Obesity Drug Development: Physiology, Pharmacology and Drug Delivery is the perfect reference for pharmacology researchers and those involved in new drug development both in academic and corporate environments. Research-physicians, endocrinologists, and nutritionists will also benefit from the comprehensive overview of treatments covered in this book.
Table of Contents
Part I Foundations and historical development on Anti-Obesity Drugs1. Introduction
2. Historical overview of drug development and therapeutics
3. Neuroendocrine consideration
4. Alternative therapies
5. Comorbidities and their impact on therapies
6. Challenges for anti-obesity drug development FDA approved versus non-conventional and non-drug therapy of obesity
Part II Drug targets involved in progression and treatment of obesity
7. GLP1R and GIPR agonists
8. Incretin/Glucagon
9. RM-493 and Liraglutide
10. Pramlintide and metreleptin
11. Growth hormone
12. Farnesoid X receptor (FXR) and membrane bound bile acid receptor (GPR131)
13. Gut Microbiota Matrix metalloproteinase (MMPs) Drug delivery technologies
Part III Drugs
14. Orlistat
15. Liraglutide
16. Lorcaserin
17. Semaglutide
18. Setmelanotide
19. Tirzepatide
20. Combination Therapies:
a. phentermine/topiramate
b. naltrexone/bupropion
Part IV - Natural Products
21. Chitosan
22. Chromium Picolinate
23. Conjugated Linoleic Acid (CLA)
24. Glucomannan
25. Green Tea Extract
26. Green Coffee Extract
27. Guar Gum
28. Hoodia
29. 7-Keto-DHEA
30. Ephedra
31. Bitter Orange

